EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF

June-Young Koh, Doo Ri Kim, Sohee Son, Hwanhee Park, Kyung-Ran Kim, Sunwoo Min, Ha Seok Lee, Byung Woo Jhun, Eun-Suk Kang, Inkyung Jung, Ji-Man Kang, Yae-Jean Kim und 1 weitere

Journal of Clinical Immunology · 2024

DOI: 10.1007/s10875-024-01687-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von June-Young Koh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. Hauptthemen laut MEDLINE: Gain of Function Mutation, Pyrazoles, STAT1 Transcription Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Basic Science (KR), Korea Advanced Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with STAT1 gain-of-function (GOF) mutations often exhibit autoimmune features. The JAK1/2 inhibitor ruxolitinib can be administered to alleviate autoimmune symptoms; however, it is unclear how immune cells are molecularly changed by ruxolitinib treatment. Then, we aimed to investigate the trnscriptional and epigenetic status of immune cells before and after ruxolitinib treatment in a patient with STAT1 GOF.

Methods

A patient with a heterozygous STAT1 GOF variant (p.Ala267Val), exhibiting autoimmune features, was treated with ruxolitinib, and peripheral blood mononuclear cells (PBMCs) were longitudinally collected. PBMCs were transcriptionally analyzed by single-cell cellular indexing of the transcriptomes and epitopes by sequencing (CITE-seq), and epigenetically analyzed by assay of transposase-accessible chromatin sequencing (ATAC-seq).

Results

CITE-seq analysis revealed that before treatment, the patient’s PBMCs exhibited aberrantly activated inflammatory features, especially IFN-related features. In particular, monocytes showed high expression levels of a subset of IFN-stimulated genes (ISGs). Ruxolitinib treatment substantially downregulated aberrantly overexpressed ISGs, and improved autoimmune features. However, epigenetic analysis demonstrated that genetic regions of ISGs—e.g., STAT1 , IRF1 , MX1 , and OAS1 —were highly accessible even after ruxolitinib treatment. When ruxolitinib was temporarily discontinued, the patient’s autoimmune features were aggravated, which is in line with sustained epigenetic abnormality.

Conclusions

In a patient with STAT1 GOF, ruxolitinib treatment improved autoimmune features and downregulated aberrantly overexpressed ISGs, but did not correct epigenetic abnormality of ISGs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gain of Function MutationPyrazolesSTAT1 Transcription FactorHumansLeukocytes, MononuclearNitrilesPyrimidines

Stichwörter der Autor:innen

ATAC sequencingInborn errors of immunityJAK inhibitorSTAT1 GOF

Substanzen

NitrilesPyrazolesPyrimidinesruxolitinibSTAT1 protein, humanSTAT1 Transcription Factor

Autor:innen und Institutionen

  • Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
  • Genome Insight, Inc., Daejeon, 34051, Republic of Korea.
  • Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University, Seoul, 06351, Republic of Korea.
  • Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, 14584, Republic of Korea.
  • Department of Pediatrics, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, 51472, Republic of Korea.
  • Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.

ORCID-Profile: Eui-Cheol Shin

Förderung

  • Institute for Basic Science (KR)
  • Korea Advanced Institute of Science and Technology

Zitieren

APA

Koh, J. Y., Kim, D. R., Son, S., Park, H., Kim, K. R., Min, S., Lee, H. S., Jhun, B. W., Kang, E. S., Jung, I., Kang, J. M., Kim, Y. J., & Shin, E. C. (2024). Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01687-9

Vancouver

Koh JY, Kim DR, Son S, Park H, Kim KR, Min S, et al. Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01687-9

BibTeX
@article{Koh2024,
  author = {Koh, June-Young and Kim, Doo Ri and Son, Sohee and Park, Hwanhee and Kim, Kyung-Ran and Min, Sunwoo and Lee, Ha Seok and Jhun, Byung Woo and Kang, Eun-Suk and Jung, Inkyung and Kang, Ji-Man and Kim, Yae-Jean and Shin, Eui-Cheol},
  title = {Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF},
  journal = {Journal of Clinical Immunology},
  year = {2024},
  doi = {10.1007/s10875-024-01687-9}
}
Kostenlos starten →